BMRN

Short volume Short volume 50% of volume (3.0σ)

9d ago

News BioMarin Reveals Dwarfism Study Data, Stock Soars

11d ago

News BioMarin gains on Voxzogo phase 3 results

12d ago

News Ionis, Alnylam, BioMarin up as Citi starts at Buy on catalyst and growth outlook

13d ago

News BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026

14d ago

News BioMarin (BMRN) Q2 Revenue Jumps 16%

14d ago

News BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030

14d ago

News BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients

14d ago

News BioMarin: EPS Surges Past Expectations

14d ago

News Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today

14d ago

News Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?

14d ago

News BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish

14d ago

News Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical

14d ago

News BioMarin rare disease biologic meets only 1 of 2 endpoints in phase 3 trial

14d ago

Insider trade Sale by Gregory R Friberg (EVP, Chief R&D Officer)

21d ago

News Here are the major earnings after the close Monday

27d ago

News BioMarin outlines $3.825B-$3.925B 2026 revenue outlook driven by Amicus integration and 20% growth target

28d ago

Short volume Short volume 66% of volume (4.7σ)

32d ago

Short volume Short volume 68% of volume (5.3σ)

32d ago

News CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)

37d ago

SEC filing BMRN Announces $1.5B Amicus Acquisition, French FDI Clearance Secured, Deal to Close April 27

39d ago

SEC filing BMRN Halts VOXZOGO Trials in Turner Syndrome, SHOX, ACAN Deficiencies After SCFE Events; Phase 2 CANOPY Continues; 10K Patient-Years Safety Data Shows No SCFE Cases

78d ago

Insider trade Sale by Charles Greg Guyer (EVP, Chief Technical Officer)

81d ago

News BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz

83d ago

Insider trade Sale by Gregory R Friberg (EVP, Chief R&D Officer)

95d ago